$9.7 M

TNXP Mkt cap, 10-Jun-2019
Tonix Pharmaceuticals Net income (FY, 2018)-26.1 M
Tonix Pharmaceuticals EBIT (FY, 2018)-26.3 M
Tonix Pharmaceuticals Cash, 31-Dec-201825 M

Tonix Pharmaceuticals Income Statement

Annual

USDFY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

R&D expense

2.6m4.7m35.5m28.5m13.3m17.6m

General and administrative expense

4.1m6.2m12.7m10.4m7.9m8.8m

Operating expense total

6.7m10.9m48.2m39.0m21.3m26.3m

EBIT

(6.7m)(10.9m)(48.2m)(39.0m)(21.3m)(26.3m)

Interest expense

1.6m4.0k

Interest income

108.0k127.0k168.0k233.0k

Net Income

(9.4m)(10.9m)(48.1m)(38.8m)(21.1m)(26.1m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

R&D expense

4.1m5.2m6.8m8.9m10.3m10.7m7.5m5.5m3.0m3.9m5.2m9.2m

General and administrative expense

2.0m2.2m2.9m2.9m3.0m3.3m2.3m2.1m2.1m1.9m1.8m3.9m

Operating expense total

6.0m7.4m9.7m11.8m13.3m14.0m9.8m7.6m5.1m5.8m7.0m13.1m

EBIT

(6.0m)(7.4m)(9.7m)(11.8m)(13.3m)(14.0m)(9.8m)(7.6m)(5.1m)(5.8m)(7.0m)(13.1m)

Interest expense

5.0k15.0k21.0k

Interest income

31.0k49.0k53.0k109.0k

Net Income

(6.0m)(7.4m)(9.7m)(11.8m)(13.2m)(14.0m)(9.8m)(7.6m)(5.1m)(5.8m)(6.9m)(13.0m)

Tonix Pharmaceuticals Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Cash

1.8m8.2m19.2m18.9m25.5m25.0m

Accounts Receivable

598.6m

Current Assets

2.0m8.6m46.4m27.1m26.4m26.1m

PP&E

350.0k150.0k91.0k43.0k

Total Assets

2.1m8.7m47.0m27.5m26.8m26.3m

Accounts Payable

3.0m872.0k1.3m1.4m

Current Liabilities

1.1m2.2m6.7m2.1m2.1m2.7m

Total Liabilities

1.2m2.2m6.8m2.1m2.1m2.7m

Additional Paid-in Capital

16.8m33.2m142.7m166.6m187.0m212.2m

Retained Earnings

(102.4m)(141.2m)(162.4m)(188.5m)

Total Equity

958.7k6.5m40.3m25.4m24.6m23.7m

Financial Leverage

2.2 x1.3 x1.2 x1.1 x1.1 x1.1 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

43.9m46.2m58.2m48.7m33.0m8.4m14.9m15.6m19.9m29.3m19.3m16.7m

Current Assets

44.8m46.9m60.0m50.3m57.2m30.7m33.7m29.2m23.4m30.2m20.7m18.2m

PP&E

306.0k316.0k327.0k383.0k349.0k315.0k132.0k102.0k78.0k65.0k

Total Assets

45.1m47.3m60.5m50.9m57.8m31.3m34.3m29.8m23.8m30.5m21.0m18.4m

Accounts Payable

2.0m2.8m2.4m2.1m1.9m944.0k841.0k1.4m1.3m1.6m

Current Liabilities

2.4m3.5m3.5m4.6m5.1m3.9m4.2m2.6m1.8m1.8m2.4m2.5m

Total Liabilities

2.7m1.9m2.4m2.5m

Additional Paid-in Capital

80.6m89.1m120.9m122.0m141.7m143.7m156.2m160.8m168.3m185.6m187.9m191.3m

Retained Earnings

(37.9m)(45.4m)(64.0m)(75.8m)(89.0m)(116.4m)(126.2m)(133.8m)(146.3m)(156.9m)(169.3m)(175.4m)

Total Equity

42.7m43.8m56.9m46.2m52.7m27.3m30.0m27.1m22.0m28.7m18.6m15.8m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x

Tonix Pharmaceuticals Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(9.4m)(10.9m)(48.1m)(38.8m)(21.1m)(26.1m)

Depreciation and Amortization

14.3k17.0k161.0k206.0k70.0k54.0k

Accounts Payable

130.6k(60.0k)1.6m(2.2m)424.0k106.0k

Cash From Operating Activities

(5.7m)(8.5m)(42.5m)(37.3m)(19.1m)(24.0m)

Cash From Investing Activities

(35.8k)(15.0k)(24.2m)16.6m7.2m(6.0k)

Cash From Financing Activities

7.5m15.0m47.7m20.5m18.5m23.5m

Interest Paid

35.2k3.0k

Income Taxes Paid

82.0k

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(6.0m)(7.4m)(9.7m)(11.8m)(13.2m)(14.0m)(9.8m)(31.4m)(5.1m)(15.6m)(6.9m)(13.0m)

Depreciation and Amortization

163.0k50.0k15.0k30.0k

Accounts Payable

2.0m2.8m2.4m2.1m1.9m(2.1m)841.0k490.0k(32.0k)342.0k

Cash From Operating Activities

(31.9m)(14.2m)(6.8m)(12.3m)

Purchases of PP&E

(2.0k)(4.0k)

Cash From Investing Activities

12.7m7.2m(2.0k)(4.0k)

Cash From Financing Activities

15.6m17.4m532.0k3.5m

Tonix Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.1 x